Effect of interferon α-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 N-acetyltransferase-2 activities in patients with chronic active hepatitis C

被引:40
作者
Becquemont, L
Chazouilleres, O
Serfaty, L
Poirier, JM
Broly, F
Jaillon, P
Poupon, R
Funck-Brentano, C
机构
[1] St Antoine Univ Hosp, Dept Pharmacol, Paris, France
[2] St Antoine Univ Hosp, Dept Hepatol, Paris, France
[3] St Antoine Univ Hosp, Clin Invest Ctr, Paris, France
[4] Fac Med Lille, UA 2679, F-59045 Lille, France
关键词
D O I
10.1067/mcp.2002.124468
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Back round: Interferon alpha (IFN-alpha) is thought to be responsible for cytochrome P450 (CYP)-dependent drug interactions mediated by a decrease in CYP activities. Objectives: The objectives are to determine whether IFN-alpha and ribavirin can alter pretreatment CYP1A2, CYP2D6, CYP3A4 and N-acetyltransferase-2 activities after 1 month of treatment. Methods: Enzymatic activities were determined among 14 patients with chronic active hepatitis C before IFN-alpha (3 . 10(6) U, 3 times a week) and ribavirin introduction and after 1 month of treatment. During both study periods, subjects received 80 mg dextromethorphan and 140 mg caffeine (1,3,7-trimethylxanthine [137X]). CYP3A4, CYP2D6, and NAT2 activities were assessed by use of urinary metabolic ratios of 3-methoxymorphinan/dextromethorphan, dextrorphan/dextromethorphan, and 5-acetylamino-6-formylamino-3-methyluracil (AFMU)/1-methylxanthine(1X). The plasma paraxanthine/caffeine ratio was used to measure CYP1A2 activity. Results: CYP3A4 and CYP2D6 activities tended to increase after 1 month of antiviral therapy, but the change did not reach statistical significance. CYP1A2 and NAT2 activities were not significantly modified after 1 month of antiviral treatment pretreatment activities were significantly lower than those previously observed in healthy volunteers for CYP2D6 (mean +/- SD, 148 139 versus 759 692; P=.0008) and CYP3A4 (0.18 +/- 0.06 versus 0.52 +/- 0.72; P=.0006). This difference was no longer statistically significant after 1 month of treatment, because CYP2D6 and CYP3A4 activities improved in 7 patients. Conclusion: In patients with chronic hepatitis C, pretreatment CYP3A4 and CYP2D6 activities were significantly lower than those observed in healthy volunteers. These differences disappeared after 1 month of antiviral treatment because of the restoration of these CYP activities in about half of the patients.
引用
收藏
页码:488 / 495
页数:8
相关论文
共 26 条
  • [11] CRAIG PI, 1993, HEPATOLOGY, V17, P230, DOI 10.1016/0270-9139(93)90082-X
  • [12] Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations
    Fuhr, U
    Rost, KL
    Engelhardt, R
    Sachs, M
    Liermann, D
    Belloc, C
    Beaune, P
    Janezic, S
    Grant, D
    Meyer, UA
    Staib, AH
    [J]. PHARMACOGENETICS, 1996, 6 (02): : 159 - 176
  • [13] The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease
    Glue, P
    Schenker, S
    Gupta, S
    Clement, RP
    Zambas, D
    Salfi, M
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (05) : 417 - 421
  • [14] PREDICTION OF PHENOTYPE FOR ACETYLATION AND FOR DEBRISOQUINE HYDROXYLATION BY DNA-TESTS IN HEALTHY-HUMAN VOLUNTEERS
    GRAF, T
    BROLY, F
    HOFFMANN, F
    PROBST, M
    MEYER, UA
    HOWALD, H
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (04) : 399 - 403
  • [15] Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients
    Grieco, A
    Castellano, R
    Matera, A
    Marcoccia, S
    Di Rocco, P
    Ragazzoni, E
    Vecchio, FM
    Gasbarrini, G
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (05) : 460 - 466
  • [16] Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions
    Khakoo, S
    Glue, P
    Grellier, L
    Wells, B
    Bell, A
    Dash, C
    Murray-Lyon, I
    Lypnyj, D
    Flannery, B
    Walters, K
    Dusheiko, GM
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (06) : 563 - 570
  • [17] Medical progress: Hepatitis C virus infection.
    Lauer, GM
    Walker, BD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 41 - 52
  • [18] Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    McHutchison, JG
    Gordon, SC
    Schiff, ER
    Shiffman, ML
    Lee, WM
    Rustgi, VK
    Goodman, ZD
    Ling, MH
    Cort, S
    Albrecht, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1485 - 1492
  • [19] DEPRESSION OF DRUG-METABOLIZING ACTIVITY IN THE HUMAN LIVER BY INTERFERON-ALPHA
    OKUNO, H
    KITAO, Y
    TAKASU, M
    KANO, H
    KUNIEDA, K
    SEKI, T
    SHIOZAKI, Y
    SAMESHIMA, Y
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (04) : 365 - 367
  • [20] Effects of interferon-cv on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C
    Pageaux, GP
    le Bricquir, Y
    Berthou, F
    Bressot, N
    Picot, MC
    Blanc, F
    Michel, H
    Larrey, D
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (06) : 491 - 495